Lymphoma: The Roleof Nurses in the Treatment Process



Similar documents
Treatment of low-grade non-hodgkin lymphoma

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Lymphomas after organ transplantation

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Guidelines for the Management of Follicular Lymphoma

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

Your NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Frequency of NHL Subtypes in Adults

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells

Mantle Cell Lymphoma Understanding Your Treatment Options

Leukaemia and lymphoma what s the difference?

Outline of thesis and future perspectives.

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Family Caregiver s Guide to Hospice and Palliative Care

SMALL CELL LUNG CANCER

Palliative Care for Children. Support for the Whole Family When Your Child Is Living with a Serious Illness

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

SPECIALTY CASE MANAGEMENT

Non-Hodgkin s lymphomas (NHLs) are a

How do I find the best place to get treatment for my lymphoma?

Understanding How Existing and Emerging MS Therapies Work

Cytotoxic and Biotherapies Credentialing Programme Module 2

RADIATION THERAPY FOR LYMPHOMA. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

Heart transplantation

Cycle frequency: Every four weeks Total number of cycles: 6-8

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

ADVANCE DIRECTIVE. A LIVING WILL A Directive To Withhold Or To Provide Treatment. A Durable Power Of Attorney FOR HEALTH CARE

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

Disease Modifying Therapies for MS

Lymphoma and palliative care services

Lymphoma Diagnosis and Classification

Disease Modifying Therapies for MS

CHOP Chemotherapy Regimen for Lymphoma Information for Patients

OVARIAN CANCER TREATMENT

Hospice and Palliative Care: Help Throughout Life s Journey. John P. Langlois MD CarePartners Hospice and Palliative Care

David Loew, LCL MabThera

BREAST CANCER TREATMENT

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

WM: Managing the Side Effects of Treatment

Trastuzumab (Herceptin ) for patients with metastatic breast cancer

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

Non-Hodgkin Lymphoma Richard Orlowski, MD

PRIMARY LUNG CANCER TREATMENT

What s New With HER2?

Prior Authorization Guideline

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

UW MEDICINE PATIENT EDUCATION. Xofigo Therapy. For metastatic prostate cancer. What is Xofigo? How does it work?

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

The Cancer Patient Journey. Dr. Jaco Fourie

Summary of the risk management plan (RMP) for Accofil (filgrastim)

Lymphoma. Starting Point. Diagnosed with Lymphoma?

Saint Francis Kidney Transplant Program Issue Date: 6/9/15

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Multiple Myeloma Understanding your diagnosis

CVP Chemotherapy Regimen for Lymphoma Information for Patients

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

VAD Chemotherapy Regimen for Multiple Myeloma Information for Patients

Future strategies for myeloma: An overview of novel treatments In development

Contra Costa Health Services Sue Dickerson, RN, OCN Nishant Shah, MD, MPH

Circle of Life: Cancer Education and Wellness for American Indian and Alaska Native Communities. Group Discussion True False Not Sure

Treating Chronic Hepatitis C. A Review of the Research for Adults

Hepatitis C treatment What to expect.

ESPEN Congress Florence 2008

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

DIFFUSE LARGE B-CELL LYMPHOMA

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Stress is linked to exaggerated cardiovascular reactivity. 1) Stress 2) Hostility 3) Social Support. Evidence of association between these

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

ACUTE MYELOID LEUKEMIA (AML),

What is a Stem Cell Transplantation?

Key Facts about Influenza (Flu) & Flu Vaccine

ONCOLOGY MANAGEMENT. Controlling Cancer-Related. Costs in Your Population. Intelligent Value. October 2012

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Fast Facts: Sézary Syndrome

Cancer services children s CSCF v3.2

Transcription:

Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland

LymphomaManagement Watch & Wait Chemotherapy Single agent Alkylating agents (cyclophosphamide, chlorambucil) Purine nucleoside analogues (fludarabine, 2-CdA) Combination chemotherapy CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone) CHOEP or EPOCH (CHOP + etoposide) CVP (cyclophosphamide + vincristine + prednisone) FC (fludarabine+cyclophosphamide) Immunotherapy Monoclonal antibodies Targeted therapy Radiotherapy Radioimmunotherapy Stem cell transplantation Source: Lymphoma Learning Programme for Nurses and Allied Healthcare Professionals (EBMT SNWG 2014)

Typesof LymphomaTreatment The choice of treatment mainly depends on the: Type of lymphoma Hodgkin Lymphoma, NHL subtype Disease stage (Ann Arbor classification) and location How quickly the cancer is growing Indolent or aggressive lymphoma Patient age Age-adjusted International Prognostic Index (aaipi) risk level Feasibility of dose-intensified approaches Eligibility for stem cell transplant (SCT) Presence of other health problems? Clinical trial eligibility Source: Lymphoma Learning Programme for Nurses and Allied Healthcare Professionals (EBMT SNWG 2014)

Nursing Care Assessments and follow-up Treatment administration and management of side effects Providing information, advice and emotional support Source: Liptrott S. IEO 2009; www.mskcc.org 4

Patient Support During Watch-and-wait Providing: Information and advice Expectations, follow-up Emotional support and reassurance Instructions for personal care Managing uncertainty Adopting a healthy lifestyle may help Eatinga healthydiet Maintaining a healthy weight Alcohol in moderation Stoppingsmoking Regular exercise Avoid stress Source: ElpheeEE.OncolNursForum. 2008 May;35(3):449-54.

Patient Support During Chemotherapy Provide information about the treatment plan Treatment schedule and duration Venous access device (if applicable) Anticipated side effects e.g. infections, explaining the symptoms and how to avoid them, particularly if blood cell counts are low Contacting the medical team if necessary Address fertility issues and provide support Management of side-effects neutropenia/ mucositis/ n&v. Source: Nagel T. RN. 2004 Oct;67(10):25-6, 28-30.

Patient Support During Immunotherapy Counselling patients on treatment administrations and anticipated outcomes and side-effects Dosing schedule Important safety information (hep B reactivation, Progressive multifocal leukoencephalopathy (PML), infusion related reactions) Important administration precautions Premedication (prophylactic antipyretic and antihistamine) Source: Long JM. Clin J Oncol Nurs. 2007 Feb;11(1 Suppl):13-21., Shankland et al 2012.

Patient Support During Immunotherapy Monitoring of vital signs (heart rate, blood pressure, respiratory rate) during and after the first infusion Providing supportive care, as required e.g. reassuring the patient about chills and shaking, until symptoms resolve Source: Long JM. Clin J Oncol Nurs. 2007 Feb;11(1 Suppl):13-21. Severe reactions typically occur with 1 st infusion, onset 30-120 mins Close monitoring patients: Pre-existing cardiac or pulmonary conditions, Experienced prior cardiopulmonary adverse reactions, High numbers of circulating malignant cells ( 25,000/mm 3 ) We need to know our patients!

Patient Support During Radiotherapy Provide information about the treatment and its side-effects Support and care before treatment: address patient concerns give instructions on skin care to minimise complications and discomfort address fertility issues assess for infection, skin integrity, dehydration, and sufficient haemoglobin level Premedication Management of side effects Source: Quinn LK. Oncology Nurse Advisor May 2010:35-36; Poirier P. Nursing: Research and Reviews. 2013(3):47-57.

Patient Support Pre-and Post-transplant Counselling patients on the procedure and anticipated outcomes and complications Premedication before SCT, to reduce unwarranted symptoms Ensuring the patient is hydrated before, during and after stem cell infusion Providing follow-up care to help prevent and treat complications Source: Brown M. Nurs Stand. 2010 Nov 17-23;25(11):47-56.

Patient Support Pre-and Post-transplant Discharge plan and home care taking into consideration the type of transplant and the risk of complications Ensuring consistent communication between outpatient and home caregivers Note: Unit-specific recommendations should be followed. Source: Brown M. Nurs Stand. 2010 Nov 17-23;25(11):47-56.

PatientSupport EmergingTherapies Emerging therapies for relapsed/refractory NHL Source: Chao MP. Cancer Manag Res. 2013 Aug 23;5:251-69. We need to be up-to-date!

Supportive and Palliative Care Supportive Care Aims to alleviate the symptoms and complications of cancer, and to reduce or prevent the toxicities of cancer treatment Includes: Providing advice and information regarding care options, practical, and social needs Providing help with emotional and physical needs Assisting in symptom relief Providing contacts for care and support Support groups Source: www.who.int/cancer/palliative

Supportive and Palliative Care Palliative Care Provides relief from pain and other distressing symptoms Enhances quality of life May also positively influence the course of illness Integrates the psychological and spiritual aspects of patient care Offers a support system to: Help patients live as actively as possible until death and Help the family cope during the patients illness Source: www.who.int/cancer/palliative

Special Patient Groups Paediatric patients Supporting parents and family Dealing with uncertainty Adolescents and young adults Unique psychosocial challenges Elderly patients Susceptibility & unpredictable toxicity Co-morbidity and drug interactions Pregnant patients Treatment during pregnancy? MDT approach Source: Lymphoma Learning Programme for Nurses and Allied Healthcare Professionals (EBMT SNWG 2014)

Summary Nurseshavea keyrolein the treatment process Educationand supportare the cornerstoneof nursing care BUT. weneedto keepup to date and respondto our patients needs. www.ebmt-swiss-ng.org